Airborne acquired by GF Capital
MINNEAPOLIS Airborne was acquired by GF Capital Private Equity Fund, the company announced.
Terms of the deal were not disclosed.
GF Capital named Martha Morfitt Airborne’s new CEO.
Morfitt most recently served as CEO and a director of CNS before that company’s acquisition by GlaxoSmithKline in December 2006.
“Airborne occupies a unique place in the nutritional supplement market,” stated Neil Shapiro, co-founder and managing director GF Capital. “We firmly believe in the company and its products, and believe that there’s tremendous opportunity for us to grow together. As CEO, [Morfitt] has a proven ability to lead companies to profitable growth, expanding their brands and product offerings in the process.”
FDA approves generic OTC allergy medication
ROCKVILLE, Md. The Food and Drug Administration has approved a generic version of an OTC allergy drug, FDA records show.
The agency approved Anmeal Pharmaceuticals’ cetirizine hydrochloride syrup in the 5 mg-per-5 milliliter strength.
The drug is a generic version of Johnson & Johnson’s Zyrtec. Amneal is the 10th company to gain FDA approval for a generic version of the drug. J&J switched Zyrtec from a prescription to an OTC drug last year.
Genetic disorder may delay diagnosis of IBD in children
INDIANAPOLIS New findings related to an uncommon genetic disorder may impact the diagnosis and treatment of inflammatory bowel disease, the most common chronic gastrointestinal illness in children and teens. Researchers from the United States and Canada have identified a genetic defect not previously known to be a cause of chronic granulomatous disease, an inherited disorder with recurrent bacterial and fungal infections. Some patients also develop gastrointestinal inflammation. CGD, which occurs in 1-in-200,000 patients, is usually diagnosed in childhood.
In addition to providing insight into CGD, a condition in which an enzyme defect prevents white blood cells in the body from killing invading bacteria, the new findings highlight how abnormal white blood cell function can predispose individuals to IBD, and may help provide insight into why IBD develops. Crohn’s disease and ulcerative colitis are the most common forms of IBD.
The research was led by Mary Dinauer of the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine and Riley Hospital for Children. The new findings are reported in the Oct. 8 print edition of the journal Blood.
“We now know that a genetic defect that selectively affects the production of oxidants inside of white blood cells can cause gastrointestinal symptoms of CGD,” Dinaur said. “Exploring the gene defect’s role in inflammatory bowel disease and immune processes will be a key priority in the future.”